类风湿关节炎患者启动生物/靶向合成改善病情抗风湿药后糖皮质激素停用:真实世界人群分析
基于真实世界人群登记数据,分析2006-2021年启动首个b/tsDMARD时合用糖皮质激素(GC)的RA患者,3个月和6个月GC停用率分别为26.2%和36.8%。校正混杂因素后,抗TNF和抗CD20治疗与GC停用可能性低于JAKi,6个月时CTLA4-Ig亦低于JAKi;JAKi与抗IL6无显著差异。
要点
- 启动b/tsDMARD时约半数RA患者合用GC,3个月和6个月停用率仅26.2%和36.8%。
- 抗TNF和抗CD20治疗与GC停用可能性低于JAKi,6个月时CTLA4-Ig亦低于JAKi。
- JAKi与抗IL6治疗在3个月和6个月GC停用上无统计学显著差异。
核心结论
- 真实世界中RA患者启动b/tsDMARD时GC使用比例高,但3个月和6个月停用GC的比例有限。
- 与JAKi相比,抗TNF、抗CD20及6个月时CTLA4-Ig治疗与GC停用可能性降低独立相关,而抗IL6与JAKi无显著差异。
研究设计与样本
- 基于真实世界人群登记数据,分析2006-2021年启动首个生物制剂或JAK抑制剂且初始合用GC的RA患者。
- 共2865例RA患者启动b/tsDMARD,其中1421例(49.6%)初始合用GC,纳入分析。
- 采用逻辑回归模型计算3个月和6个月GC停用的比值比(OR),并校正潜在混杂因素。
主要发现
- 1421例合用GC患者中位年龄57.0(48.0-65.0)岁,女性1162例(81.8%),中位病程2.0(1.0-5.0)年。
- 总体3个月和6个月GC停用率分别为26.2%和36.8%。
- 3个月时,校正年龄、既往长期GC使用、当前csDMARD使用和高血压后,抗TNF(OR 0.520,95%CI 0.383-0.707)和抗CD20(OR 0.134,95%CI 0.057-0.278)与GC停用可能性低于JAKi显著相关。
- 6个月时,校正年龄、既往长期GC使用和高血压后,抗TNF(OR 0.560,95%CI 0.412-0.761)、抗CD20(OR 0.461,95%CI 0.274-0.764)和CTLA4-Ig(OR 0.492,95%CI 0.254-0.919)与GC停用可能性低于JAKi独立相关。
- JAKi与抗IL6治疗在3个月和6个月两个时间点GC停用均无统计学显著差异。
临床怎么用
- 启动b/tsDMARD时合用GC的RA患者应定期评估GC停用可能性,3个月和6个月停用率仍有限。
- 选择b/tsDMARD时,若目标是尽早停用GC,可参考不同药物与GC停用可能性的关联,JAKi相对抗TNF、抗CD20和CTLA4-Ig与更高停用可能性相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate glucocorticoids (GCs) discontinuation after the initiation of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients, using data from a real-world population-based registry. METHODS: We analyzed data from RA patients who initiated their first biologics or Janus kinase inhibitors (JAKi) during the period of 2006-2021. bDMARDs included anti-tumor necrosis factor (anti-TNF), anti-interleukin6 (anti-IL6), anti-CD20, and Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig). Patients who were concurrently on GCs at the initiation of bDMARD or JAKi therapy were included. Logistic regression models were used to calculate the odds ratios (ORs) of GC discontinuation at 3 and 6 months, adjusting for potential confounders. RESULTS: Out of 2865 RA patients on b/tsDMARDs, 1421 patients (49.6%) (median age: 57.0 [48.0-65.0] years; female: 1162 [81.8%]; median disease duration: 2.0 [1.0-5.0] years) were on additional GC therapy initially. The overall 3-month and 6-month GC discontinuation rates were 26.2% and 36.8%, respectively. At month 3, after adjusting for age, prior chronic GC use, current csDMARDs use and hypertension, anti-TNF (OR 0.520, 95% CI: 0.383-0.707) and anti-CD20 (OR 0.134, 95% CI: 0.057-0.278) treatments were significantly associated with a lower likelihood of GC discontinuation compared to JAKi therapy. At month 6, after adjusting for age, prior chronic GC use and hypertension, anti-TNF therapy (OR 0.560, 95% CI 0.412-0.761), anti-CD20 therapy (OR 0.461, 95% CI 0.274-0.764), and CTLA4-Ig (OR 0.492, 95% CI 0.254-0.919) were independently associated with a reduced likelihood of GC discontinuation compared to JAKi therapy. No statistically significant difference was observed between JAKi and anti-IL6 therapy at either time point. CONCLUSIONS: In the real-world setting, a high prevalence of RA patients was on GCs at the time of the initiation of b/tsDMARDs. However, only a limited proportion of these patients were able to discontinue GCs by months 3 and 6. Initiation of JAKi therapy was associated with a greater likelihood of glucocorticoid discontinuation compared with selected bDMARDs, while no statistically significant difference was observed relative to anti-IL6 therapy.
引用
- Jin Y, Meng H, Lam SH, et al. Glucocorticoid discontinuation in patients with rheumatoid arthritis who initiated biologic or targeted synthetic agents: a real-world population-based analysis. Semin Arthritis Rheum. 2026. PMID: 42809897. doi:10.1016/j.semarthrit.2026.153083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。